<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>GIDS Research Radar · Jiangsu, China</title>
  <link>https://globalinfectiousdisease.com/research/</link>
  <description>Published infectious-disease literature filtered to Jiangsu, China.</description>
  <language>en</language>
  <atom:link href="https://globalinfectiousdisease.com/research/rss/countries/cn-js.xml" rel="self" type="application/rss+xml" />
  <lastBuildDate>Sat, 07 Nov 2026 03:45:11 GMT</lastBuildDate>
  <item>
    <title>Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1371-journal-pmed-1003953-977a43c9/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1371-journal-pmed-1003953-977a43c9/</guid>
    <pubDate>Thu, 26 May 2022 00:00:00 GMT</pubDate>
    <description>The findings support flexibility in combining viral-vectored and recombinant protein COVID-19 vaccines in immunization programs, based on trial immunogenicity and safety data.</description>
    <category>COVID-19</category>
    <category>SARS</category>
    <category>Influenza</category>
    <category>Vaccination</category>
    <category>Vaccine safety</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-21-00681-2-6171133c/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-21-00681-2-6171133c/</guid>
    <pubDate>Fri, 01 Apr 2022 00:00:00 GMT</pubDate>
    <description>Findings support that a booster at 8 months can restore waned anti-SARS-CoV-2 immunity in adults receiving the inactivated vaccine.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Vaccine safety</category>
    <category>Randomised controlled trial</category>
  </item>
  <item>
    <title>Improving the surveillance and response system to achieve and maintain malaria elimination: a retrospective analysis in Jiangsu Province, China</title>
    <link>https://papers.globalinfectiousdisease.com/research/articles/10-1186-s40249-022-00939-3-8ffbd535/</link>
    <guid isPermaLink="true">https://papers.globalinfectiousdisease.com/research/articles/10-1186-s40249-022-00939-3-8ffbd535/</guid>
    <pubDate>Mon, 21 Feb 2022 00:00:00 GMT</pubDate>
    <description>Sustained vigilance and active surveillance are described as critical to preserving elimination gains, with possible lessons for similar settings globally.</description>
    <category>Malaria</category>
    <category>Surveillance</category>
    <category>Travel medicine</category>
    <category>Climate and environment</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
</channel>
</rss>
